Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Issues Quarterly Earnings Results, Beats Expectations By $0.15 EPS

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) issued its quarterly earnings results on Tuesday. The company reported $0.79 EPS for the quarter, topping the consensus estimate of $0.64 by $0.15, Zacks reports. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.74%. The company had revenue of $15.73 billion during the quarter, compared to analyst estimates of $15.77 billion. Bayer Aktiengesellschaft updated its FY 2026 guidance to 1.200-1.346 EPS.

Bayer Aktiengesellschaft Trading Up 0.3%

BAYRY traded up $0.03 on Thursday, hitting $11.09. The company had a trading volume of 970,254 shares, compared to its average volume of 1,280,881. The firm has a market cap of $43.58 billion, a P/E ratio of -17.33 and a beta of 0.62. Bayer Aktiengesellschaft has a 1 year low of $6.31 and a 1 year high of $14.85. The company’s fifty day moving average price is $11.27 and its 200 day moving average price is $10.96. The company has a current ratio of 1.01, a quick ratio of 0.63 and a debt-to-equity ratio of 1.22.

Wall Street Analyst Weigh In

Several brokerages have issued reports on BAYRY. UBS Group raised shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research note on Monday, March 16th. Zacks Research raised shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research note on Friday, May 8th. Finally, DZ Bank raised shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research report on Thursday, April 9th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.